Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA phase 3 revaccination schedule study in adults aged 60 years and older
2019-004680-51Phase 3Active
- Sponsor
- GSK
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV), sponsored by GSK. Primary endpoint: Humoral immune response in terms of RSV-A neutralizing antibody geometric mean titers. Started Nov 2020; status: active.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-004680-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004680-51.